RE:RE:Re: SCRNThanks for your thoughts on adbio . However question needs to be answered as to what is this acquisition giving to other shareholders in exchange of 33 million shares !! Mr. Ryu will need to answer the question including the ones you posted . This is a lot of shares for nothing given back in return to other shareholders so far . Not even a word in company update is telling me Mr. Ryu is hoping no one will notice . By the the way the appoined director of adbio
Michael Yeung at the time of acquisiton is long gone .
"We are pleased that the acquisition of Add Biomedical is now finalized. This expansion is a strategic acquisition that advances us further into the health screening industry. We are excited for this new addition of the company and look forward to sharing our future plans." - Lena Kozovski, CEO.
Terms of the Acquisition
Pursuant to the Amended Share Purchase Agreement, the Company issued 33,000,000 Units of the Company, each Unit consisting of one common share and one common share purchase warrant. Each warrant exercisable to purchase one common share at an exercise price of $0.15 per share for 24 months. No finder's fee was payable in connection with the Acquisition.
Operations of Add Biomedical Upon Completion of the Acquisition
Add Biomedical has become a wholly-owned operating subsidiary of the Company. The Company has appointed Michael Yeung as the new director of Add Biomedical, Lena Kozovski as Chief Executive Officer and Paul Haber as Chief Financial Officer of Add Biomedical following the closing of the Acquisition.